Baogang Shi, Xiaobo Xu, Xiaofeng Xia, Quanyong Wang
{"title":"Ultrasound-Guided Optimization of Preoperative Chemoradiotherapy Using ¹³¹I SPECT/CT for Enhanced Targeting in Differentiated Thyroid Carcinoma.","authors":"Baogang Shi, Xiaobo Xu, Xiaofeng Xia, Quanyong Wang","doi":"10.1177/10849785251376447","DOIUrl":null,"url":null,"abstract":"<p><p>To properly target tumors during preoperative chemoradiotherapy, differentiated thyroid carcinoma (DTC) must be careful. This method increases treatment success and decreases recurrence. Ultrasound coupled with SPECT/CT may provide novel localization and dose planning possibilities. Many systems solely use anatomical or functional imaging. This may result in insufficient dosage delivery and wasted radiation exposure to healthy tissues. These issues are addressed by Dual-Modality Imaging-Guided Adaptive Chemoradiotherapy Planning (DMI-ACP). This innovative approach combines real-time ultrasound imaging with 6 Å SPECT/CT imaging for precise tumor delineation and tailored dosimetry. This system enables clinicians to adjust chemoradiotherapy regimens by seamlessly integrating functional iodine absorption data with anatomical characteristics, thereby targeting therapy to cancerous areas. The outcomes of this method for patients with DTC were promising, including better lesion targeting, reduced radiation exposure to healthy tissues, and improved chemotherapeutic dose distribution. In clinical evaluations, the DMI-ACP framework demonstrated a sensitivity of 94% and a specificity of 89% in identifying malignant lesions compared with traditional imaging techniques. Furthermore, the integration of adaptive planning resulted in a 20% improvement in tumor control probability and a 15% reduction in exposure to surrounding healthy tissue, as assessed through dosimetric analysis. 2023075 Nanjing Drum Tower Hospital Group Suqian Hospital/The Affiliated Suqian Hospital of Xuzhou Medical University.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biotherapy and Radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10849785251376447","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
To properly target tumors during preoperative chemoradiotherapy, differentiated thyroid carcinoma (DTC) must be careful. This method increases treatment success and decreases recurrence. Ultrasound coupled with SPECT/CT may provide novel localization and dose planning possibilities. Many systems solely use anatomical or functional imaging. This may result in insufficient dosage delivery and wasted radiation exposure to healthy tissues. These issues are addressed by Dual-Modality Imaging-Guided Adaptive Chemoradiotherapy Planning (DMI-ACP). This innovative approach combines real-time ultrasound imaging with 6 Å SPECT/CT imaging for precise tumor delineation and tailored dosimetry. This system enables clinicians to adjust chemoradiotherapy regimens by seamlessly integrating functional iodine absorption data with anatomical characteristics, thereby targeting therapy to cancerous areas. The outcomes of this method for patients with DTC were promising, including better lesion targeting, reduced radiation exposure to healthy tissues, and improved chemotherapeutic dose distribution. In clinical evaluations, the DMI-ACP framework demonstrated a sensitivity of 94% and a specificity of 89% in identifying malignant lesions compared with traditional imaging techniques. Furthermore, the integration of adaptive planning resulted in a 20% improvement in tumor control probability and a 15% reduction in exposure to surrounding healthy tissue, as assessed through dosimetric analysis. 2023075 Nanjing Drum Tower Hospital Group Suqian Hospital/The Affiliated Suqian Hospital of Xuzhou Medical University.
术前放化疗时,分化型甲状腺癌(DTC)必须谨慎选择合适的放化疗目标。这种方法提高了治疗成功率,减少了复发。超声结合SPECT/CT可能提供新的定位和剂量计划的可能性。许多系统仅使用解剖或功能成像。这可能导致剂量输送不足和对健康组织的辐射暴露浪费。这些问题通过双模成像引导的适应性放化疗计划(DMI-ACP)来解决。这种创新的方法结合了实时超声成像与6 Å SPECT/CT成像精确肿瘤划定和量身定制的剂量。该系统使临床医生能够通过无缝整合功能性碘吸收数据和解剖学特征来调整放化疗方案,从而靶向治疗癌区。该方法用于DTC患者的结果是有希望的,包括更好的病灶靶向,减少对健康组织的辐射暴露,改善化疗剂量分布。在临床评估中,与传统成像技术相比,DMI-ACP框架在识别恶性病变方面的敏感性为94%,特异性为89%。此外,通过剂量学分析评估,适应性规划的整合导致肿瘤控制概率提高20%,对周围健康组织的暴露减少15%。2023075南京鼓楼医院集团宿迁医院/徐州医科大学宿迁附属医院
期刊介绍:
Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.
The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.